Publication: 2093

Publication: 2093

Disease-free survival (DFS) and treatment effect estimates of the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance]; N063D) in the adjuvant treatment of HER2-positive early breast cancer (EBC) patients according to hormone receptor status

DOI

URL

Google Scholar

Citation:: Ann Oncol vol 25 (suppl 4)

Meeting Instance:: ESMO 2014
Year:: 2014
Type:: Abstract
Sub type:: Published Only
Funding:: NCTN
Endpoint:: Secondary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: pub

Note:

Methodological:: No
Biospecimen:: No
SDC:: No

Parents:: None
Children:: 2247

Program:: OGC
Primary Committee:: Breast
Sec. Committees:

Pharmas:
Grants:

Corr. Author:: Edith A. Perez
Authors:: Edith A. Perez Eileen Holmes José Baselga Evandro de Azambuja Amylou C. Dueck Giuseppe Viale Jo Anne Zujewski Aron Goldhirsch Rocco Crescenzo Kathleen I. Pritchard Antonio C. Wolff Christian Jackisch Istvan Lang Michael Untch Ian Smith Frances Boyle Binghe Xu Henry Gomez Richard D. Gelber Martine Piccart-Gebhart

Networks:: LAPS-MD017, LAPS-MN026, LAPS-NY016, PR028

Study: NCCTG-N063D
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 3

Keywords: